No­vo Nordisk ex­ecs had on­ly one drug on their mind when they came call­ing at For­ma. Here's the in­side sto­ry of their $1.1B buy­out

No­vo Nordisk nev­er hes­i­tat­ed in its pur­suit of For­ma’s sick­le cell drug etavopi­vat. Dat­ing back to the ear­ly part of 2021, No­vo ex­ecs were reach­ing out to For­ma to see if they could work out a col­lab­o­ra­tion. And from the start, For­ma wasn’t much in­ter­est­ed in that sort of an al­liance.

But things got se­ri­ous af­ter For­ma laid out its up­date on the pro­gram at ASH in ear­ly De­cem­ber.

The da­ta were from a small Phase I tri­al, and For­ma con­clud­ed:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER